The transcription factor E2F1 is a key component of cell cycle that acts to transactivate genes required for S phase entry. Thus, it plays an important role in cellular proliferation, oncogenesis and dierentiation. In order to investigate its potential implication in human lung carcinogenesis, we studied E2F1 protein expression by Western blotting and immunohistochemistry in a series of 58 human lung tumours of all histological types. We showed that E2F1 product was overexpressed in 92% (24/26) of small cell lung carcinoma (SCLC) and in 50% (5/10) of large cell neuroendocrine carcinoma (LCNEC) whereas it was undetectable in 90% (10/11) of adenocarcinoma and 82% (9/11) of squamous carcinoma when compared to corresponding normal lung. No ampli®cation was found but an increase in E2F1 mRNA expression was detected in 75% (18/24) of SCLC overexpressing E2F1 product. In these tumours and in contrast with NSCLC, upregulation of E2F1 product was associated with its nuclear accumulation and with overexpression of several of its target-genes. Moreover, E2F1 overexpression in NE lung tumours was signi®-cantly associated with a high KI67 index (P50.0001) as well as a Bcl-2:Bax ratio 41 (P50.001). Overall, these results demonstrate a distinct pattern of E2F1 expression in human lung tumours and suggest that its deregulation could be involved in the carcinogenesis of SCLC.
Introduction
E2F1, a critical regulator of cell cycle progression, was the ®rst identi®ed member of a family of transcription factors generically referred to as E2F (Nevins, 1992) . This protein plays a pivotal role in G 1 to S phase transition by transactivating speci®c target-genes (Dyson, 1998; Helin, 1998 for review) . The majority of E2F1-regulated genes encode proteins involved in DNA replication and/or in S phase progression such as DNA polymerase a, thymidine kinase (TK), dihydrofolate reductase (DHFR), Mini Chromosome Maintenance 2 to 7 (MCM), cdc6, cyclin A and cyclin E, cdc2, c-myc and E2F1 itself (DeGregori et al., 1995; Helin, 1998) . E2F1 function is tightly regulated during cell cycle by the product of the retinoblastoma tumour suppressor gene (pRb). In G 1 , unphosphorylated pRb represses the transactivating activity of E2F1/DP1 heterodimeric complexes (Flemington et al., 1993; Weintraub et al., 1995; Zhang et al., 1999) . In late G 1 , phosphorylation of pRb by cyclin-dependent kinases (cdk) induces its dissociation from E2F1/DP1 heterodimers and progression into S phase (Mittnacht, 1998) . In late S, cyclin A/cdk2 complex binds to E2F1 and phosphorylates DP1, thereby inactivating E2F1/ DP1 activity.
Ectopic expression of E2F1 induces DNA synthesis in quiescent immortal rodent cells (Johnson et al., 1993; Qin et al., 1994; Shan and Lee, 1994; Shan et al., 1996) , confers neoplastic properties to immortalized cells , and increases tumorigenesis in transgenic mice that lack p53 function (Pierce et al., 1998) . Moreover, old transgenic mice overexpressing E2F1 develop spontaneous tumours in a variety of tissues (Pierce et al., 1999) . Altogether, these results confer oncogenic properties to E2F1. Paradoxically, mice lacking E2F1 also develop lymphoma or pulmonary adenocarcinoma suggesting that E2F1 can function as a tumour suppressor (Field et al., 1996; Yamasaki et al., 1996) , probably via its ability to induce p53-dependent or independent apoptosis (Wu and Levine, 1994; DeGregori et al., 1997; Phillips et al., 1999) . Thus, the ability of E2F1 to promote cell cycle progression and tumour growth or apoptosis and tumour suppression might be tissue-speci®c.
Human lung cancers are divided into two dierent sub-classes based on the 1999 WHO classi®cation of lung cancer (Travis et al., 1999) : (i) non small cell lung carcinoma (NSCLC) that include squamous carcinoma, adenocarcinoma and large cell carcinoma; (ii) neuroendocrine (NE) lung tumours that include carcinoid (typical and atypical), large cell neuroendocrine carcinoma (LCNEC) and small cell lung carcinoma (SCLC), the last one being the most aggressive lung tumours. Pathways involving p53 and pRb tumour suppressor genes are frequently deregulated during lung tumorigenesis. p53 is inactivated in 70% of human lung tumours either by missense (Chiba et al., 1990; Brambilla et al., 1993) or null mutations (Gazzeri et al., 1994) . pRb pathway is dierentially disrupted in NSCLC and high grade NE tumours. Whereas loss of pRb protein expression (through mutations and/or loss of transcription) occurs in 85% of SCLC and LCNEC (Gouyer et al., 1998) , pRb function is abolished in 85% of NSCLC either through loss of p16
INK4a protein expression (Xu et al., 1996; Gazzeri et al., 1998a) , and/ or cyclin D1 overexpression (Brambilla et al., 1997) . As E2F1 is one key component of these two pathways (O'Connor et al., 1995; Bates et al., 1998; Kowalik et al., 1998) , any alterations aecting them, especially pRb inactivation, are thought to deregulate its activity. However, since E2F1 activation could contribute to either proliferation or apoptosis depending on the tissular context, the consequences of pRb inactivation on E2F1 expression and activity might dier during tumorigenesis according to each category of tumour.
E2F1 was poorly analysed in lung tumours (DeMuth et al., 1998; Volm et al., 1998) . To get further into its putative role in lung carcinogenesis, we studied E2F1 protein expression and mRNA in a series of 58 lung tumours of all histological types, in comparison with normal lung tissue. To assess E2F1 transactivating activity in each tumour category, we also studied the expression level of several of its known target-genes. Our results identify a distinct pattern of E2F1 expression between NSCLC and SCLC and suggest that E2F1 upregulation and hyperactivity could contribute to the carcinogenesis of SCLC.
Results

Distinct pattern of E2F1 expression in human lung tumours
E2F1 protein expression was studied on a panel of 58 lung tumour tissue samples by Western-blotting using two monoclonal antibodies (Table 1, Figure 1 ). E2F1 product was undetectable in all normal lung tissues studied ( Figure 1a ) and poorly detectable in 2/11 (18%) squamous carcinoma and 1/11 (9%) adenocarcinoma (Figure 1b,c) . In contrast, when compared to normal lung, a signi®cative overexpression of E2F1 was observed in 24/26 (92%) small cell lung carcinoma and 5/10 (50%) large cell NE carcinoma (Table 1, Figure 1d ). Same results were obtained with the two anti-E2F1 antibodies used. Overall, E2F1 product was Figure 2 ). Four cases displayed discordance: in three of them where necrosis was intense, E2F1 staining was positive using IHC analysis whereas Western analysis was negative. In the last case, a faint band was observed by Western blot but tumour cells were negative in IHC analysis. Taken together, our results demonstrated a distinct pattern of E2F1 protein expression in human lung tumours.
Subcellular distribution of E2F1 in human lung tumours
As subcellular localization of E2F members could in¯uence their activity, their interaction with targetgenes as well as their degradation by the ubiquitinproteasome pathway (Hateboer et al., 1996; Hofmann et al., 1996; Lindeman et al., 1997; Vigo et al., 1999) , we next investigated the subcellular distribution of E2F1 in lung tumours on whole imprint preparations using indirect immuno¯uorescence in addition to classical immunohistochemistry revealed with peroxydase on tissue sections. Twenty of the 58 samples included in this study comprising one normal lung tissue, ®ve SCLC and ®ve LCNEC that overexpressed (6200) E2F1 product, ®ve squamous carcinoma and ®ve adenocarcinoma that expressed undetectable level of E2F1 by Western blotting were analysed. In all NSCLC tested, E2F1 product was never detected in the nucleus of tumour cells (Figure 3b ). Absence of nuclear staining was con®rmed by counterstaining with Hoechst. However, we observed a faint E2F1 cytoplasmic staining in many NSCLC cells (Figure 3b ) when compared to negative control. In contrast, all SCLC cells exhibited a strong nuclear staining thereby con®rming overexpression of E2F1 in these set of tumours ( Figure 3c ). Neither normal lung cells ( Figure  3a ) nor stromal cells exhibited nuclear staining, although the last cells might display some cytoplasmic staining. Same results were obtained using IHC analysis (see Figure 2 ).
Overexpression of E2F1 is associated with increased E2F1 mRNA transcripts
We next investigated if E2F1 protein upregulation in SCLC could be the consequence of E2F1 gene ampli®cation and/or increase in E2F1 gene transcription. Using Southern blotting, we did not detect any ampli®cation of E2F1 gene in all SCLC tested when compared to normal lung tissues (data not shown). Analysis of E2F1 mRNA was performed by Northern blotting in the 24 SCLC overexpressing E2F1 protein.
High levels of E2F1 transcripts were detected in 18 of those tumours (75%) when compared to normal lung tissues where E2F1 transcripts were undetectable using this technique (Figure 4 ). In the 6/24 remaining cases, E2F1 transcriptional level was undetectable as in normal lung despite high level of E2F1 protein expression.
Overexpression of E2F1 correlates with upregulation of some of its target-genes
To further analyse E2F1 activity in lung tumours, we studied by Western blot analysis the expression of several well-known E2F1-target genes. When compared to normal lung tissues (Figure 5a ), high levels of cyclins A and E, cdc2 and DHFR products were detected in 22/24 (90%) SCLC and 5/5 (100%) LCNEC that overexpressed E2F1 (Figure 5b ). In one case (4%) SCLC, cyclin A was undetectable despite overexpression of other target-genes. In contrast, expression of these four proteins was weak in 17/19 (95%) NSCLC that exhibited undetectable E2F1 product (Figure 5c,d) . Again, in 3/11 (27%) squamous lung carcinoma, cyclin A was slightly detectable despite low level of E2F1 expression (Figure 5d ; lanes 9 ± 11) suggesting that additional factors might regulate its expression in this subset of tumour. Taken together, these results indicated that upregulation of E2F1 protein expression in SCLC was associated with overexpression of some E2F1-targets genes.
Relationships between E2F1, p53, pRb and hp14 ARF status in lung carcinoma Status of p53, pRb and hp14 ARF had been previously analysed in this series of tumours (Brambilla et al., 1993; Gazzeri et al., 1994 Gazzeri et al., , 1998a Gouyer et al., 1998) . In these tumours, pRb function was inactivated, either by loss-of-function mutations or p16
INK4a loss and/or cyclin D1 overexpression in 29/36 (80%) NE tumours and 18/22 (82%) NSCLC respectively. However, we did not ®nd any correlation between the status of E2F1 and pRb inactivation in all tumours studied (data not shown). There was no inverse nor direct correlation linking E2F1 and hp14 ARF or p53 expression in any histological tumour class. However, we noticed that overexpression of E2F1 was frequently associated with inactivation of hp14 ARF [as detected by negative immunostaining (Gazzeri et al., 1998b) ] (20/ 36, 69%) and/or of p53 [as indicated by p53-positive immunoreactivity (Gazzeri et al., 1994) ] (18/36, 50%) in NE lung tumours (Table 2) .
Correlation between E2F1, KI67 and Bcl-2:Bax levels in human lung carcinoma
In human lung tumours, E2F1 might mediate either apoptosis or cellular proliferation depending on the context. Thus, we ®nally investigated in each tumoral subtype, the relationships between E2F1 protein expression, the well-known proliferative index KI67 (Gerdes et al., 1984) and the equilibrium of two main factors of cell susceptibility to apoptosis, Bcl-2 and Bax (Brambilla et al., 1996) . KI67 proliferative index was signi®cantly higher in NE lung tumours when compared to NSCLC (44+19 versus 21+13; P50.0001; Table 3 ). Furthermore, a high KI67 index correlated with overexpression of E2F1 product in all histological subtypes (P50.0001).
Susceptibility to apoptosis was investigated through IHC analysis of both Bcl-2 and Bax products. Indeed, we had previously demonstrated that a Bcl-2:Bax ratio 41 correlated with a lower apoptotic index in NE lung tumours (Brambilla et al., 1996) . We showed that Bcl-2 mean score was signi®cantly higher in NE lung tumours when compared to NSCLC (202+109 versus 41+54; P50.0001; Table 3 ). Furthermore, a Bcl-2:Bax ratio 41 was signi®cantly associated with NE phenotype (P50.001) and E2F1 overexpression (P50.001) whereas NSCLC exhibited a Bcl-2:Bax ratio 51 and low level of E2F1 product (Table 3) . Overall, these results strongly suggest that E2F1 overexpression in high grade neuroendocrine lung tumours might mediate cellular proliferation rather than apoptosis.
Discussion
We have investigated E2F1 protein expression in a series of 58 human lung tumours and demonstrated that NSCLC and NE carcinoma displayed distinct pattern of E2F1 expression. Whereas E2F1 product was undetectable by Western blot analysis and IHC in nearly all NSCLC analysed, it was upregulated in high grade NE lung tumours. As we previously showed that pRb function was invalidated (either by mutations or loss of p16
INK4a and/or cyclin D1 overexpression) in 80% of all lung tumours tested in this study (Gazzeri et al., 1998a; Gouyer et al., 1998) , our present data suggest that inactivation of pRb pathway does not To get clues onto the mechanism of E2F1 upregulation in SCLC, we analysed DNA ampli®cation and mRNA expression. Although ampli®cation was not found, we detected an increase in E2F1 mRNA expression in the majority of those tumours overexpressing E2F1 protein. An increase in E2F1 transcription normally occurs in late G 1 in response to growth stimuli (Sherr, 1996) but can also be detected in response to oncogenic stimuli such as myc . Moreover, E2F1 has been reported to stimulate its own transcription (Johnson et al., 1994; Neuman et al., 1994) . These data and the present study suggest that, in SCLC, deregulated oncogenic signals could induce a primary increase of E2F1 gene transcription further ampli®ed by protein accumulation. Interestingly, some tumours exhibited a high E2F1 protein level despite absence of mRNA overexpression. E2F1 protein level is tightly controlled by ubiquitin-proteasome mediated proteolysis (Campanero and Flemington, 1997; Vandel and Kouzarides, Figure 5 E2F1, cyclin A, cyclin E, DHFR and cdc2 protein expressions in normal lung tissues (a), SCLC (b), adenocarcinoma (c) and squamous carcinoma (d). Western-blot analysis was performed as described in Materials and methods and actin was used as a loading control. To allow comparison between each histological type, Western-blots were revealed in the same conditions and results for each case were con®rmed in at least two independent experiments. (b) Overexpression of E2F1 was associated with high level of cyclin E, A, cdc2 and DHFR (tumours 1, 3 to 7). Lane 2: tumour representative of 2/26 SCLC that do not overexpress E2F1 and subsequent cyclin E, cyclin A, cdc2 and DHFR expression. Lane 8: tumour representative of 2/24 SCLC tested in which overexpression of E2F1 does not correlate with overexpression of cyclin A despite overexpression of cyclin E, cdc2 and DHFR. (c, d) In NSCLC, as in SCLC, correlation was observed between levels of E2F1 and several of its targets 1999) and association with pRb has been shown to protect E2F1 from degradation (Hateboer et al., 1996; Hofmann et al., 1996) . Since pRb was lost in 80% of the NE tumours studied, E2F1 accumulation in these tumours is probably not the result of protection by pRb. Additionally, the protein p45 SKP2 was recently shown to directly interact with E2F1 and to negatively regulate its stability (Marti et al., 1999; Wade-Harper and Elledge, 1999) . We have studied p45 SKP2 protein expression by IHC in our series of tumours but we could not ®nd any correlation between p45 SKP2 and E2F1 expression (data not shown). Thus, it remains to elucidate if accumulation of E2F1 in SCLC could be associated with a defect in its proteolysis.
We observed E2F1 accumulation in the nuclei of SCLC tumoral cells that was consistent with the expression of an active E2F1 product (de la Luna et al., 1996; Allen et al., 1997) and found a strong correlation between the expression of E2F1 and several of its target-genes including cyclins A and E. Interestingly, in SCLC overexpressing E2F1, we also detected heterodimeric complexes between E2F1 and DP1 or E2F1 and mdm2 (data not shown). Since E2F1 transactivating activity is highly enhanced upon dimerization with DP1 (Wu et al., 1995) and binding of mdm2 (Martin et al., 1995) , our results highly suggest that E2F1 is not only upregulated but also transcriptionally active in SCLC. In contrast and interestingly, absence of E2F1 nuclear staining correlated with weak level of E2F1 target-genes expression in NSCLC. Thus, despite loss of pRb repression, free E2F1 product might be transcriptionally inactive in this subset of tumors.
Therefore, what might be the biological consequences of E2F1 expression in lung carcinogenesis? During tumorigenesis, E2F1 has been implicated both as an oncogene (Johnson et al., 1993; Qin et al., 1994; Pierce et al., 1998 Pierce et al., , 1999 or a tumour suppressor gene (Field et al., 1996; Yamasaki et al., 1996; Pierce et al., 1999) depending on the context and on its ability to induce cell proliferation and/or p53-dependent orindependent apoptosis. In lung tissues, we noticed that E2F1 protein expression displayed opposite patterns between NSCLC and SCLC making attractive the possibility that this protein could play a distinct role during tumorigenesis of these two tumour subsets. Since E2F1 knock-out mice develop pulmonary adenocarcinoma (Field et al., 1996) , its inactivation in NSCLC could contribute to a defective apoptosis of tumoral cells. Conversely, unbalance between apoptosis and cell proliferation could be implicated in the tumorigenesis of SCLC. In this subset of tumour, we observed a correlation between E2F1 expression and KI67 proliferative index suggesting that E2F1 might be involved in their high proliferative pattern. In contrast, the ability of E2F1 to induce apoptosis might be (Gazzeri et al., 1998b) and although statistically not signi®cant, a correlation between E2F1 overexpression and p53 inactivation and/or hp14 ARF loss was detected in SCLC. As E2F1 can induce p53-dependent apoptosis via its ability to transactivate hp14 ARF (Bates et al., 1998) , inactivation of p53 or hp14 ARF could give an advantage to the proliferative eects of E2F1 versus its pro-apoptotic functions. Moreover, as we observed that high grade neuroendocrine lung tumours including SCLC expressed a Bcl-2:Bax ratio 41 (Brambilla et al., 1996 and this study), Bcl-2 could further inhibit the apoptosis of SCLC tumour cells overexpressing E2F1 and contribute to their proliferation. According to this, sensitivity of oesophageal cancer cells to E2F1-mediated apoptosis was recently related to dierential expression of Bcl-2 family member proteins (Yang et al., 2000) .
Overall, our data identify a distinct pattern of E2F1 protein expression in human lung tumours and demonstrate its upregulation in SCLC, the most proliferative and aggressive lung tumours. In these tumours, E2F1 could therefore act as an oncogene being an essential actor of uncontrolled cellular proliferation, for example by counteracting the negative eects of cyclin-cdk inhibitors. This could explain why these tumours are so actively proliferative despite their high content in p16
INK4a (Kelley et al., 1997 ; data not shown) and p27
Kip1 products (Yatabe et al., 1998 ; data not shown). These ®ndings have obvious conceptual implications in the promising strategic therapy targeting E2F1 function. They should aim at neutralizing E2F1 production in SCLC in order to inhibit their proliferation and inducing its expression in NSCLC in order to restitute apoptosis.
Material and methods
Tissue samples
Tissue samples were taken at surgical resection of lung tumours or node metastases at mediastinoscopy. They were immediately frozen and kept at 7808C until use. They consisted of 11 squamous carcinoma; 11 adenocarcinoma; 10 LCNEC and 26 SCLC according to the 1999 WHO international histological classi®cation of lung tumours (Travis et al., 1999) .
Antibodies
Monoclonal antibodies (mAbs) included anti-cdc2p34 (sc-54, Santa-Cruz Biotechnology, Santa Cruz, CA, USA), anticyclin E (clone HE12, Euromedex, Souelweyersheim), anti-DHFR (Dihydrofolate Reductase; clone 49, Transduction Laboratories, Lexington, KY, USA) and two anti-human E2F1 (clone Ab-4, Neomarkers and clone KH95, Pharmingen). Rabbit polyclonal antibodies included anti-actin (20 ± 33, Sigma-Aldrich, L'Isle d'Abeau) and anti-cyclin A (C-22, sc-160, Santa-Cruz, CA, USA).
Immunohistochemistry (IHC)
E2F1, KI67, Bcl-2 and Bax immunostaining were performed on frozen sections. For E2F1 immunostaining, two monoclonal E2F1 antibodies KH95 (Santa-Cruz; 1/100) and Ab-4 (Neomarkers; 1/50; data not shown) were used. Three step immunohistochemical method was applied on 5 mm thick frozen sections taken in the immediate vicinity of samples used for Western-blot. After E2F1 primary antibodies, the secondary antibody was anti-mouse (1/1250) and third step was ABC complex (Streptavidin-Biotin peroxidase; Dako). Cases were recovered as positive when at least 20% of tumour cells showed obvious nuclear staining. Only nuclear staining was considered to assess immunoreactivity. Cytoplasmic staining was never considered in the assessment of E2F1 expression. It was observed in addition to nuclear staining in a subset of squamous carcinoma and adenocarcinoma. Normal lung cells, lymphocytes and vessels were all negative. KI67 immunostaining was performed using a mouse monoclonal antibody from Immunotech (1/100). KI67 percentage of positive cells was established on 300 cells count. Bcl-2 and Bax immunostaining were performed as previously described (Brambilla et al., 1996) using a Bcl-2 monoclonal antibody from Dako (1/100) and a Bax polyclonal antibody N-19 from Santa-Cruz (1/200). Scores of immunostaining were calculated by multiplying the percentage of labeled cells with the intensity (1+,2+,3+) of staining for a total score gain from 0 to 300. The Bcl-2/Bax ratio was established by dividing the two total scores.
Indirect immunofluorescence
Whole imprint preparations were performed by gentle pressing tumoral frozen tissue to silane-coated glass slides, air dried and stored at 7808C until use. Slides were treated for 10 min at room temperature in ice-cold nuclei isolation buer [5 mM HEPES (pH 8), 50 mM KCl, 10 mM MgSO 4 and 3 mM DTT], incubated at 7208C during 10 min in nuclei isolation buer supplemented with 0.25% Triton X-100, washed twice with PBS and ®xed for 5 min in acetone at 7208C. After ®xation, slides were washed, saturated and incubated overnight with primary antibody (anti-human E2F1, Ab-4, 1/200) at 48C. After three PBS washes, slides were exposed to Alexa TM 488 goat anti-mouse-IgG (H+L) conjugate (2 mg/ml;1/500, Interchim, MontlucË on) for 30 min at room temperature and washed twice in PBS. Normal mouse IgG at the same concentration as the primary antibody served as a negative control. The slides were counterstained with Hoechst and preparations were observed using an Olympus microscope (206magni®cation), captured by a Coolview CCD camera (Photonic Science) and digitally saved using Visilog. The images were further processed by using Photoshop (Adobe).
Western-blot analysis
Tissues samples were lysed in ice-cold lysis buer [5 mM EDTA, 150 mM NaCl, 100 mM Tris (pH 8), 0.5% Na deoxycholate, 0.5% NP40, 0.5% SDS, 0.1% aprotinin, 2 mg/ml leupeptin, 2 mg/ml pepstatin, and 1 mM PMSF] for 30 min and centrifugated (30 min, 15 000 g). In order to ensure appropriate detection, a molecular weight marker was loaded onto each gel. Proteins (40 mg) were denatured in Laemmli buer [60 mM Tris HCl (pH 6.8), 20% glycerol, 10% b-mercaptoethanol, 4.6% SDS, and 0.003% bromophenol blue], separated by 10 ± 12% sodium dodecyl sulfate polyacrylamide gel (SDS ± PAGE) and electroblotted on PVDF membrane (Hybond P, Amersham, Les Ulis, France). The membrane was then incubated for 2 ± 3 h at room temperature with primary Ab in 2% non-fat milk TPBS, washed three times, incubated with horseradish peroxydaseconjugated goat anti-mouse or anti-rabbit Abs (Jackson ImmunResearch Laboratories, West Grove, PE) for 30 min and revealed using enhanced chemoluminescence detection kit (ECL; Amersham).
Northern blot analysis
Total RNA was extracted according to the method of Chomczynski and Sacchi (1987) . Ten mg of total RNA were fractionated by electrophoresis in 1% agarose-formaldehyde gels and transferred onto a nylon membrane (Hybond N, Amersham). Equivalent RNA loading was veri®ed by ethidium-bromide staining of gels before transfer onto membranes. A BamH1-1.35 kb full lenght human E2F1 cDNA fragment (kindly provided by Dr K Helin, Milan) was used as a probe and was radiolabelled using the random primed DNA labelling kit (Roche Diagnostics). The membranes were prehybridized and hybridized in 50% formamide, 56Denhardt's solution, 50 mM phosphate buer (pH 6.5), 56SSC, 0.1% SDS, and 2.5 mg/ml salmon sperm DNA for 42 h at 428C. The most stringent ®nal wash was for 20 min at 568C in 0.26SSC, and 0.1% SDS. Membranes were exposed for autoradiography at 7808C for at least 3 days.
